Search Results for agency_names:"Health and Human Services Department"

The National Clinical Care Commission will hold its tenth virtual meeting on February 17, 2021, to discuss ways to improve federal programs related to diabetes and its complications. The meeting will include updates from subcommittees and potential action plans. Public comments are encouraged, with opportunities for oral remarks during the meeting, which require prior registration. Written comments can also be submitted by email. The Commission is authorized by the National Clinical Care Commission Act and overseen by the Department of Health and Human Services.

The National Heart, Lung, and Blood Institute is announcing a virtual meeting of the National Heart, Lung, and Blood Advisory Council on April 23, 2025. The meeting is open to the public and will be videocast on the NIH website. Those interested in attending or making an oral presentation should contact Charisee Lamar in advance. Security procedures for visitors and additional information about the meeting can be found on the NIH website.

The National Institute of Mental Health is holding a closed meeting on February 4, 2025, from 3:00 p.m. to 5:00 p.m. to review and evaluate grant applications under the BRAIN Initiative. The meeting will be conducted virtually and is closed to the public to protect personal privacy and confidential information. Rebecca Steiner Garcia is the Scientific Review Officer overseeing this meeting. The meeting is part of the federal mental health research grant program.

The National Institute of Environmental Health Sciences announced upcoming closed meetings as per section 10(d) of the Federal Advisory Committee Act. These meetings will not be open to the public to protect confidential information and personal privacy. The meeting will take place virtually on February 19, 2021, and will involve a review of grant applications. Dr. Laura A. Thomas is the contact person for further information regarding the meeting.

The National Institute of Neurological Disorders and Stroke announced a change in the meeting date for their Special Emphasis Panel. Originally scheduled for January 26, 2021, the meeting will now take place on February 24, 2021, with the time remaining the same. This meeting, held at the National Institutes of Health in Rockville, Maryland, is closed to the public. The change was documented in the Federal Register on January 19, 2021, and it modifies the previous announcement made on December 8, 2020.

The Food and Drug Administration (FDA) is removing its approval for eight different abbreviated new drug applications (ANDAs), as the companies that made these drugs informed the FDA that the drugs are no longer being sold. The companies asked the FDA to cancel these approvals, and the FDA has agreed to do so as of April 14, 2025. Even though approval is being withdrawn, the decision does not prevent the companies from filing new applications in the future if desired. Also, any existing drugs from the list that are still in stock after this date can be sold until they run out, expire, or otherwise become unsuitable.

The National Institute of Mental Health is holding a closed meeting on April 22-23, 2025, to review and evaluate grant applications. This virtual meeting will not be open to the public due to the confidential nature of the discussions, which may involve sensitive personal information and trade secrets. The meeting is part of the activities under the Federal Advisory Committee Act and will be managed by Claudio Dario Ortiz, Ph.D., a Scientific Review Officer at the NIH.

The National Institutes of Health has announced a change in the contact person for an upcoming meeting of the HIV/AIDS Intra- and Inter-personal Determinants and Behavioral Interventions Study Section. This meeting, originally detailed in the Federal Register on March 12, 2025, will take place from April 24 to April 25, 2025. The new contact is Joann Wu Shortt, Ph.D., replacing Mark Rubert, Ph.D. The meeting will be held in Bethesda, MD, and it is closed to the public.

The Food and Drug Administration (FDA) has awarded a priority review voucher to Alnylam Pharmaceuticals Inc. for their product, OXLUMO (lumasiran) injection. This product is used to treat a rare disease called primary hyperoxaluria type 1, which helps lower urinary oxalate levels in both children and adults. The voucher is part of a program set by the Federal Food, Drug, and Cosmetic Act, which recognizes drugs designed for rare pediatric diseases. The FDA is required to announce when such vouchers are awarded.

The Center for Scientific Review, part of the National Institutes of Health, announced several closed meetings scheduled in April and May 2025. These sessions aim to review and evaluate grant applications but will not be open to the public due to concerns about confidentiality and privacy, as they involve sensitive personal data and potential trade secrets. Meetings will be held as virtual gatherings and cover various topics like cell and molecular biology, oncology fellowships, and gastroenterology, among others. Contact information for the Scientific Review Officers handling each meeting is provided for further inquiries.